QRxPharma’s Moxduo Doesn’t Offer Respiratory Safety Advantage, FDA Finds
This article was originally published in The Pink Sheet Daily
Advisory committee briefing documents state that the fixed-dose combination of immediate-release morphine and oxycodone was not superior to either of its individual components with regard to oxygen desaturation rate.
You may also be interested in...
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee wants Risk Evaluation and Mitigation Strategies enhanced for all extended-release/long-acting opioids as it recommends 11-2, one abstention, against approval of Zogenix’s single-entity hydrocodone product.
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.
Switching method of administration from subcutaneous to intradermal would increase by five-fold the number of doses of Bavarian Nordic’s vaccine available to combat the outbreak; an EUA declaration would be needed to make this change, FDA commissioner Robert Califf said.